The most common grade @ or higher adverse events during the combination phase were neutropenia ( in @ -LSB- @ % -RSB- of @ patients in the olaparib plus chemotherapy group vs @ -LSB- @ % -RSB- of @ in the chemotherapy alone group ) and anaemia ( seven -LSB- @ % -RSB- vs five -LSB- @ % -RSB- ) .